Moderna And Carisma Establish Collaboration To Develop In Vivo Engineered Chimeric Antigen Receptor Monocytes For Oncology; Carisma To Receive $45M Up-front Cash Payment And Investment By Moderna In The Form Of A $35M Convertible Note